Necitumumab

Necitumumab
	Necitumumab Fab (blue) bound to EGFR (green). PDB: 6B3S
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	EGFR
Clinical data
Trade names	Portrazza
AHFS/Drugs.com	Multum Consumer Information
License data	US DailyMed: Necitumumab;
Routes of; administration	Intravenous infusion
ATC code	L01FE03 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: WARNINGRx-only;
Pharmacokinetic data
Elimination half-life	~14 days
Identifiers
CAS Number	906805-06-9 ;
DrugBank	DB09559 ;
ChemSpider	none;
UNII	2BT4C47RUI;
KEGG	D10018 ;
Chemical and physical data
Formula	C6436H9958N1702O2020S42
Molar mass	144844.87 g·mol−1
	(what is this?) (verify)

Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR).^[3] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).^[4]^[5]^[6] It was counterproductive in non-squamous non-small-cell lung carcinoma.^[6]^[7]

References

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
^ Chustecka Z (2015-11-22). "Necitumumab (Portrazza) Approved for Lung Cancer in US". Medscape.com. Retrieved 2019-09-28.
^ "Necitumumab". Approved Drugs. U.S. Food and Drug Administration. Archived from the original on 2017-01-11. Retrieved 2019-12-16.
^ ^a ^b "Portrazza: Highlights of Prescribing Information" (PDF). www.accessdata.fda.gov. 2015. Retrieved 2019-09-28.
^ Hand L (3 March 2015). "Necitumumab Fails in NSCLC". MedScape. Archived from the original on 2015-11-29. Retrieved 2015-11-25.